SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 10, 2013
(Registrant’s telephone number, including area code): (510) 651-4450
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 10, 2013, WaferGen Bio-systems, Inc. (the “Company”) entered into a severance benefits agreement with John Harland, Chief Financial Officer of the Company. The following description of the severance benefits agreement with Mr. Harland is qualified in its entirety by reference to the terms of such agreement, which is filed as Exhibit 10.1 to this current report on Form 8-K.
The severance benefits agreement provides that if Mr. Harland’s employment is terminated by the Company without Cause (as defined in the agreement) or by Mr. Harland for Good Reason (as defined in the agreement), then Mr. Harland will be entitled to receive severance benefits in the form of salary continuation payments over a 6- month period following the date of termination; provided Mr. Harland’s right to receive such severance payments is conditioned upon his execution of a waiver and release of claims against the Company.
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.